Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
New data support Merus' standard-of-care hopes as it moves ahead with late-stage testing. With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, ...
Analysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’ expectations for the bispecific antibody. The slim slice of efficacy data, which Merus presented at the 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results